Should alpha-interferon be included as standard treatment in multiple myeloma? Pro

European Journal of Cancer

Volumn 34, Issue 1, 1998, Pages 12-17

  Ludwig, H ^a   Fritz, E ^a  

^a WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUROTOXICITY; NOTE; PATIENT SATISFACTION; PRIORITY JOURNAL; VERTIGO; VOMITING;

ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; HUMANS; INTERFERON-ALPHA; MULTIPLE MYELOMA; PATIENT SATISFACTION; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS;

EID: 0031891193     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10046-6     Document Type: Article

References (69)

1. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995, 6, 467-476.
2. Einhorn S, Ahre A, Blomgren H, Johansson B, Mellstedt H, Strander H. Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha. Int J Cancer 1932, 30, 167-172.
3. Österborg A, Nilsson B, Björkholm M, Holm G, Mellstedt H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol 1990, 45, 153-157.
4. Jett R, Mantovani A, Herberman RB. Augmentation of human monocyte-mediated cytolysis by interferon. Cell Immunol 1980, 54, 425-432.
5. Harada H, Fujita T, Miyamoto M, et al. Structurally similar but functionally distinct factors, IRF-1 and 1RF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989, 58, 729-739.
6. De Maeyer-Guignard J, De Maeyer E. Immunomodulation by interferons: recent developments. Interferon 1985, 6, 69-91.
7. Einhorn S, Strander H. Interferon therapy for neoplastic diseases in man: in vitro and in vivo studies. Adv Exp Med Biol 1978, 110, 159-174.
8. Brenning G, Jernberg H, Gidlund M, Sjoeberg O, Nilsson K. The effect of alpha and gamma-interferon on proliferation and production of IgE and beta 2-micro-globulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U266 subline. Scand J Haematol 1986, 37, 280-288.
9. Ludwig H, Swetly P. In vitro inhibitor: effect of interferon on multiple myeloma stem cells. Cancer Immunol Immunother 1980, 9, 139-143.
10. Jernberg-Wiklund H, Pettersson M, Nilsson K. Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur J Haematol 1991, 46, 231-239.
11. Kimchi A. Autocrine interferon and the [suppression of the c-myc nuclear oncogene. Interferon 1987, 8, 85-110.
12. Samid D, Chang EH, Friedman RM. Development of transformed phenotype induced by a human :ras oncogene is inhibited by interferon. Biochem Biophys Res Commun 1985, 126, 509-516.
13. Princier GL, Brini AT, Kung H. IFN-alpha down-regulates the IL-6 receptor (IL-6R) by induction of endogenous IL-6. LymphokineRes 1990, 9, 570.
14. Mellstedt H, Ahre A, Björkholm M, Holm G, Johansson B, Strander H. Interferon therapy in myelomatosis. Lancet 1979, i, 245-248.
15. Ahre A, Björkholm M, Mellstedt H, et al. Human leukocyte interferon and intermittent high-dose melphalan/prednisone administration in the treatment of multiple myeloma: a randomized clinical trial. Cancer Treat Rep 1984, 68, 1331-1338.
16. Ludwig H, Cortelezzi A, Scheithauer W, et al. Recombinant interferon alpha-2c versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial. Eur J Cancer Clin Oncol 1986, 22, 1111-1116
17. Gutterman JU, Blumenschein GR, Alexanian R, et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980, 93, 399-406.
18. Costanzi JJ, Cooper MR, Scarffe JH, et al. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol 1985, 3, 654-659.
19. Ohno R, Kimura K. Treatment of multiple myeloma with recombinant interferon alpha-2a. Cancer 1986, 57, 1687-1688.
20. Case DC, Sonneborn HL, Paul SC, et al. Phase II study of rDNA alpha-2b interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 1986, 70, 1251-1254.
21. Quesada JE, Alexanian R, Hawkins M, et al. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986, 67, 275-278.
22. Oken MM, Kyle RA, Kay NE, Greipp PR, O'Connell MJ. Interferon in the treatment of refractory multiple myeloma: an Eastern Cooperative Oncology Group study. Leuk Lymphoma 1990, 1, 95-100.
23. Aapro MS, Alberts DS, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983, 10, 161-166.
24. Balkwill FR, Moodey EM. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 1985, 44, 906-908.
25. Welander CE, Morgan TM, Homesley HD, et al. Combined recombinant human interferon alpha 2 and cytotoxic agents in a clonogenic assay. Im J Cancer 1985, 35, 721-729.
26. Cooper MR, Fefer A, Thompson J, et al. Alpha-2 interferon/ melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial. Cancer Treat Rep 1986, 70, 473-476.
27. Oken MM, Kyle RA. Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma. Semin Oncol 1991, 18 (Suppl. 7), 30-32.
28. Simon R. Randomized clinical trials in oncology. Cancer 1994, 74, 2614-2619.
29. Durie BGM, Russell DH, Salmon SE. Reappraisal of plateau phase in myeloma. Lancet 1980, ii, 65-67.
30. 1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 1980, 77, 1471-1475.
31. Horoszewicz JS, Leong SS, Carter WS. Non cycling tumor cells are sensitive targets for the antiproliferative activity of human interferon. Science 1979, 206, 1091-1093.
32. Mandelli F, Awisati G, Amadori S, et al Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N EnglJ Med 1990, 322, 1430-1434.
33. Österborg A, Björkholm M, Björeman M, et al Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993, 81, 1428-1434.
34. Casassus Ph, Mahe B, Sadoun A, et al. Alpha interferon is not able to improve VMCP/VBAP chemotherapy response rate in induction phase of untreated multiple myeloma: results in the first 201 patients included in a prospective randomized study (KIF protocol). International Conference: Multiple Myeloma, From Biology to Therapy. Mulhouse, France, 1994, 69 (abstract).
35. Avilés A, Alatriste S, Talavera A, Delgado S, Rosas A. Alternating combination chemotherapy and interferon improves survival in poor prognosis multiple myeloma. Clin Oncol 1995, 7, 97-101.
36. Montuoro A, De Rosa L, De Blasio A, Pacilli L, Petti N, De Laurenzi A. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma. Br J Haematol 1990, 76, 365-368.
37. Galvez CA, Pire R, Bonamassa M. Multiple myeloma: treatment with VABP with or without recombinant alpha-2b interferon in multiple myeloma. 18th International Congress of Chemotherapy, Stockholm, Sweden, 1993, 321 (abstract).
38. Vela Ojeda J, Vazquez V, Garcia Ruiz EM, et al. A randomized clinical trial comparing chemotherapy with or without interferon alpha-2b in newly diagnosed patients with multiple myeloma. IV International Workshop on Multiple Myelomn, Rochester, Minnesota, U.S.A., 1993, 150 (abstract).
39. Scheithauer W, Cortelezzi A, Fritz E, et al. Combined α-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial. J Biol Resp Mod 1939, 8, 109-115.
40. Aitchison R, Williams A, Schey S, Newland AC. A randomised trial of cyclophosphamide with and without low dose alphainterferon in the treatment of newly diagnosed myeloma. Leukemia Lymphoma 1993, 9, 243-246.
41. The Nordic Myeloma Study Group. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Intern Med 1996, 124, 212-222.
42. Joshua DE, Penny R, Baldwin R, Laidlaw CR, Matthews JP. The study of combination therapy plus or minus Roferon A in multiple myeloma. Blood 1994, 84 (Suppl. 1), 179a (abstract).
43. Cooper MR, Dear K, Mclntyre OR, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 1993, 11, 155-160.
44. Corrado C, Pavlovsky S, Saslasky J, Lein J, Palau V, Santarelli MT. Randomized trial comparing melphalan-prednisone with or without recombinant alpha-2 interferon (r-alpha2IFN) in multiple myeloma. Proc Am Soc Clin Oncol 1989, B, 258 (abstract).
45. Garcia-Larana J, Steegmann JL, Ferez Oteyza J, et al. Treatment of multiple myeloma with melphalan/prednisone (MP) versus melphalan/prednisone and alpha-2b-inte:rferon (MP-IFN). Results of a Cooperative Spanish Group. Cong Int Soc Haematol ISH 1992, 24, 301 (abstract).
46. Capnist G, Spirano M, Damasio EE, et al. Is IFN helpful in the treatment of multiple myeloma? Preliminary results of a multicenter study of Italian NHLCSG. Proc Am Soc Clin Oncol 1993, 12, 407 (abstract).
47. Alexanian R, Barlogie B, Gutterman J. Alpha-interferon combination therapy of resistant myeloma. Am J Clin Oncol 1991, 14, 188-192.
48. Salmon SE, Beckord J, Pugh RP, Barlogie B, Crowley J. α-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group study. J Clin Oncol 1994, 12, 2405-2414.
49. Browman GP, Rubin S, Walker I, et al. Interferon-alpha-2b (IFN) maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma (PCM) : results of a randomized trial. Proc Am Soc Clin Oncol 1994, 13, 408 (abstract).
50. Westin J, Rödjer S, Turesson I. Interferon alpha-2b as maintenance therapy in multiple myeloma: effect on plateau phase duration and survival. Cong Int Soc Haematol ISH 1992, 24, 71 (abstract).
51. Peest D, Deicher X, Coldewey R, et al. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma: current results of a multicenter trial. Onkologie 1990, 13, 458-460.
52. Powles R, Raje N, Cunningham D, et al. Maintenance therapy for remission in myeloma with intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue. Stem Cells 1995, 13 (Suppl. 2), 114-117.
53. McSweeney EN, Tobias JS, Blackman G, Goldstone AH, Richards JDM. Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma. Clin Oncol 1993, 5, 378-383.
54. Ohno R. Interferons in the treatment of multiple myeloma. Int J Cancer 1987, Suppl. 1, 14-20.
55. Ahre A, Björkholm M, Österborg A, et al. High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma: a pilot study from the Myeloma Group of Central Sweden (MGCS). Eur J Haematol 1988, 41, 123-132.
56. Attal M, Huguet F, Schlaifer D, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992, 79, 1130-1136.
57. Samson D. The current position of allogeneic and autologous BMT in multiple myeloma. Leukemia Lymphoma 1992, 7(Suppl.), 33-38.
58. Malpas JS, Ganjoo RK, Johnson PW, et al. Myeloma during a decade: clinical experience in a single centre. Ann Oncol 1995, 6, 11-18.
59. Björkstrand B, Ljungman P, Bird JM, et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 1995, 13 (Suppl. 2), 140-146.
60. Harousseau L, Altai M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995, 85, 3077-3085.
61. Fossa SD, Gunderson R, Moe B. Recombinant Interferon alpha combined with prednisone in metastatic renal cell carcinoma: reduced toxicity without reduction of the response rate-a phase II study. Cancer 1990, 65, 2451-2454.
62. Alexanian R, Barlogie B, Gutterman J. Alpha-interferon combination therapy for multiple myeloma. Proceedings of the 5th Hannover Interferon Workshop, 1990, 43 (abstract).
63. San Miguel JF, Moro M, Blade J, et al. Combination of interferon and dexamethasone in refractory multiple myeloma. Hematol Oncol 1990, 8, 185-189.
64. Salmon SE, Beckord J, Pugh RP, Barlogie B, Crowley J. Alpha interferon for remission maintenance: preliminary report on the Southwest Oncology Group study. Semin Oncol 1991, 18 (Suppl. 7), 33-36.
65. Palumbo A, Boccadoro M, Garino LA, Gallone G, Frieri R, Pileri A. Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids. Eur J Haematol 1992, 49, 93-97.
66. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd edition. New York, John Wiley, 1981.
67. Clarke MT, Stewart LA. Obtaining data from randomized controlled trials: how much do we need for reliable and informative meta-analyses? Br Med J 1994, 309, 1007-1010.
68. Early Breast Cancer Trialists" Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. New Engl J Med 1988, 319, 1681-1692.
69. Ludwig H, Fritz E, Neuda J, Dune BGM. Patient preferences for interferon-alpha in multiple myeloma. J Clin Oncol (in press).